Enhanced percutaneous absorption of cilostazol nanocrystals using aqueous gel patch systems and clarification of the absorption mechanism

Yoshioka,Chiaki; Ito,Yoshimasa; Nagai,Noriaki

doi:10.3892/etm.2018.5820

Enhanced percutaneous absorption of cilostazol nanocrystals using aqueous gel patch systems and clarification of the absorption mechanism

Authors:
- Chiaki Yoshioka
- Yoshimasa Ito
- Noriaki Nagai
View Affiliations

Affiliations: Faculty of Pharmacy, Kindai University, Higashi‑Osaka, Osaka 577‑8502, Japan
Published online on: January 31, 2018 https://doi.org/10.3892/etm.2018.5820
Pages: 3501-3508

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cilostazol (CLZ), an anti-platelet agent, is primarily used following the onset of cerebral infarction. However, as CLZ is only marginally soluble in water, a strategy for patients with serious secondary conditions, such as impaired consciousness or aphagia, is required. In the present study, topical formulations containing CLZ nanocrystals (CLZnano) were designed to enhance percutaneous absorption. In addition, the mechanism of penetration of CLZnano through rat skin was investigated. A topical formulation containing CLZ nanoparticles (CLZnano gel patch) was prepared using a combination of recrystallization and ball milling of an aqueous gel. The particle size of CLZnano was 74.5±6.2 nm (mean ± standard deviation). The concentration of permeated CLZnano and penetration mechanism of the nanocrystals were measured in a percutaneous absorption experiment. The amount of penetrated CLZ, the penetration rate (Jc), the penetration coefficient through the skin (Kp) and the skin/preparation partition coefficient (Km) for the CLZnano gel patch were all significantly higher than those of the CLZ powder (CLZmicro) gel patch, the CLZnano ointment and the CLZmicro ointment. In in vitro percutaneous penetration experiments on the CLZnano gel patches, there was a positive correlation between the number of CLZnano. Following the application of the CLZnano gel patch on rat skin, 98% of penetrated CLZ was observed in nanoparticle form; for the CLZmicro gel patch, this figure was 9%. In addition, the CLZ concentrations in the plasma of rats administered the CLZnano gel patches were significantly higher than those of rats administered the CLZnano CP gel and PEG ointments. It was suggested that CLZnano (diameter <100 nm) were transferred through the intracellular spaces in the skin and then into peripheral blood vessels. To the best of our knowledge, this is the first report to elucidate the mechanism of the percutaneous penetration of nanocrystal medicines.

View Figures

View References

1	Kimura Y, Tani T, Kanbe T and Watanabe K: Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung. 35:1144–1149. 1985.PubMed/NCBI
2	Kanbayashi J, Liu Y, Sun B, Shakur Y, Yoshitake M and Czerwiec F: Cilostazol as a unique antithrombotic agent. Curr Pharm Des. 9:2289–2302. 2003. View Article : Google Scholar : PubMed/NCBI
3	Bramer SL and Forbes WP: Relative bioavailability and effects of a high fat meal on single dose cilostazol pharmacokinetics. Clin Pharmacokinet. 2(37 Suppl): S13–S23. 1999. View Article : Google Scholar
4	Jinno J, Kamada N, Miyake M, Yamada K, Mukai T, Odomi M, Toguchi H, Liversidge GG, Higaki K and Kimura T: Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J Control Release. 111:56–64. 2006. View Article : Google Scholar : PubMed/NCBI
5	Jinno J, Kamada N, Miyake M, Yamada K, Mukai T, Odomi M, Toguchi H, Liversidge GG, Higaki K and Kimura T: In vitro-in vivo correlation for wet-milled tablet of poorly water-soluble cilostazol. J Control Release. 130:29–37. 2008. View Article : Google Scholar : PubMed/NCBI
6	Rasenack N and Müller BW: Micron-size drug particles: Common and novel micronization techniques. Pharm Dev Technol. 9:1–13. 2004. View Article : Google Scholar : PubMed/NCBI
7	Gotoh F, Tohgi H, Hirai S, Terashi A, Fukuuchi Y, Otomo E, Shinohara Y, Itoh E, Matsuda T, Sawada T, et al: Cilostazol stroke prevention study: A placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis. 9:147–157. 2000. View Article : Google Scholar : PubMed/NCBI
8	Sugibayashi K: Development & Applications of Transdermal Drug Delivery Systems. CMC publishing Company; Tokyo: pp. 167–176. 2011
9	Honeywell-Nguyen PL and Bouwstra JA: Vesicles as a tool for transdermal and dermal delivery. Drug Discov Today Technol. 2:67–74. 2005. View Article : Google Scholar : PubMed/NCBI
10	Walters KA and Roberts MS: The structure and function of the skin. Marcel Dekker; New York, NY: pp. 1–40. 2002
11	Cevc G and Vierl U: Nanotechnology and the transdermal route: A state of the art review and critical appraisal. J Control Release. 141:277–299. 2010. View Article : Google Scholar : PubMed/NCBI
12	Scheuplein RJ: Mechanism of percutaneous absorption. I. Routes of penetration and influence of solubility. J Invest Dermatol. 45:334–346. 1965. View Article : Google Scholar : PubMed/NCBI
13	Watanabe T: The present conditions and the prospects of a skin applications drug. Drug Delivery System. 22:450–457. 2007. View Article : Google Scholar
14	Tsujimoto H, Hara K, Yokoyama T, Yamamoto H, Takeuchi H, Kawashima Y, Akagi K, Miwa N and Haung CC: Percutaneous absorption study of biodegradable PLGA nano-spheres via human skin biopsies. J Soc Powder Technol. 41:867–875. 2004. View Article : Google Scholar
15	Bal SM, Ding Z, van Riet E, Jiskoot W and Bouwstra JA: Advances in transcutaneous vaccine delivery: Do all ways lead to Rome? J Control Release. 148:266–282. 2010. View Article : Google Scholar : PubMed/NCBI
16	Yoshioka C, Ito Y and Nagai N: An oral formulation of cilostazol nanoparticles enhances intestinal drug absorption in rats. Exp Ther Med. 15:454–460. 2017.PubMed/NCBI
17	Franz TJ: Percutaneous absorption on the relevance of in vitro data. J Invest Dermatol. 64:190–195. 1975. View Article : Google Scholar : PubMed/NCBI
18	Nagai N, Iwamae A, Tanimoto S, Yoshioka C and Ito Y: Pharmacokinetics and antiinflammatory effect of a novel gel system containing ketoprofen solid nanoparticles. Biol Pharm Bull. 38:1918–1924. 2015. View Article : Google Scholar : PubMed/NCBI
19	DeLouise LA: Applications of nanotechnology in dermatology. J Invest Dermatol. 132:964–975. 2012. View Article : Google Scholar : PubMed/NCBI
20	Gao X, Cui Y, Levenson RM, Chung LW and Nie S: In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol. 22:969–976. 2004. View Article : Google Scholar : PubMed/NCBI
21	Moghimi SM, Hunter AC and Murray JC: Nanomedicine: Current status and future prospects. FASEB J. 19:311–330. 2005. View Article : Google Scholar : PubMed/NCBI
22	Al-Jamal WT, Al-Jamal KT, Tian B, Cakebread A, Halket JM and Kostarelos K: Tumor targeting of functionalized quantum dot-liposome hybrids by intravenous administration. Mol Pharm. 6:520–530. 2009. View Article : Google Scholar : PubMed/NCBI
23	Boisselier E and Astruc D: Gold nanoparticles in nanomedicine: Preparations, imaging, diagnostics, therapies and toxicity. Chem Soc Rev. 38:1759–1782. 2009. View Article : Google Scholar : PubMed/NCBI
24	Debbage P: Targeted drugs and nanomedicine: Present and future. Curr Pharm Des. 15:153–172. 2009. View Article : Google Scholar : PubMed/NCBI
25	Huang HC, Barua S, Sharma G, Dey SK and Rege K: Inorganic nanoparticles for cancer imaging and therapy. J Control Release. 155:344–357. 2011. View Article : Google Scholar : PubMed/NCBI
26	Huang X, Peng X, Wang Y, Wang Y, Shin DM, El-Sayed MA and Nie S: A reexamination of active and passive tumor targeting by using rod-shaped gold nanocrystals and covalently conjugated peptide ligands. ACS Nano. 4:5887–5896. 2010. View Article : Google Scholar : PubMed/NCBI
27	Ilbasmiş-Tamer S, Yilmaz S, Banoğlu E and Değim IT: Carbon nanotubes to deliver drug molecules. J Biomed Nanotechnol. 6:20–27. 2010. View Article : Google Scholar : PubMed/NCBI
28	Zhang LW, Yu WW, Colvin VL and Monteiro-Riviere NA: Biological interactions of quantum dot nanoparticles in skin and in human epidermal keratinocytes. Toxicol Appl Pharmacol. 228:200–211. 2008. View Article : Google Scholar : PubMed/NCBI
29	Garala K, Faldu N, Basu B, Bhalodia R, Mehta K and Joshi B: Chemical penetration enhancement. J Pharm Res. 2:1804–1808. 2009.
30	Nishihata T, Kamada A, Sakai K, Takahashi K, Matsumoto K, Shinozaki K, Tabata Y, Keigami M, Miyagi T and Tatsumi N: Percutaneous absorption of diclofenac in rats and humans: Aqueous gel formulation. Int J Pharm. 46:1–7. 1988. View Article : Google Scholar
31	Ahmed TA, Ibrahim HM, Ibrahim F, Samy AM, Fetoh E and Nutan MT: In vitro release, rheological, and stability studies of mefenamic acid coprecipitates in topical formulations. Pharm Dev Technol. 16:497–510. 2011. View Article : Google Scholar : PubMed/NCBI
32	Goddard ED and Gruber JV: Principles of polymer science and technology in cosmetics and personal care. Marcel Dekker, Inc.; New York-Basel: 1999, View Article : Google Scholar